9.05
+0.14(+1.57%)
Currency In USD
| Previous Close | 8.91 |
| Open | 8.94 |
| Day High | 9.12 |
| Day Low | 8.81 |
| 52-Week High | 10.28 |
| 52-Week Low | 2.99 |
| Volume | 961,224 |
| Average Volume | 2.39M |
| Market Cap | 1.37B |
| PE | -9.53 |
| EPS | -0.95 |
| Moving Average 50 Days | 7.97 |
| Moving Average 200 Days | 6.37 |
| Change | 0.14 |
If you invested $1000 in Adaptive Biotechnologies Corporation (ADPT) since IPO date, it would be worth $224.57 as of May 18, 2025 at a share price of $9.05. Whereas If you bought $1000 worth of Adaptive Biotechnologies Corporation (ADPT) shares 5 years ago, it would be worth $230.28 as of May 18, 2025 at a share price of $9.05.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025
GlobeNewswire Inc.
Apr 10, 2025 8:05 PM GMT
SEATTLE, April 10, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma
GlobeNewswire Inc.
Apr 08, 2025 12:00 PM GMT
clonoSEQ is now covered to monitor for recurrence in MCL patients who are in treatment-free remissionSEATTLE, April 08, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims
Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma
GlobeNewswire Inc.
Mar 11, 2025 12:00 PM GMT
Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the only DLBCL MRD assay available for clinical use and covered by Medicare SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) --